 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «1234567891011» |
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial primary completion date: ONYX PAS: RESOLUTE ONYX Post-Approval Study (clinicaltrials.gov) - Oct 3, 2019
P=N/A, N=510, Recruiting, Sponsor: Medtronic Vascular
Trial primary completion date: Nov 2019 --> Oct 2018
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical: Agree with @billgogas but in this case used a resolute onyx. Radial strength key in this lesion subset (Twitter) - Oct 2, 2019
- paclitaxel / Generic Mfg.
Drug-Coated Balloon Versus Drug-Eluting Stent for the Treatment of Small-Vessel Disease: 2-Year Clinical Outcomes of the RESTORE SVD China Randomized Trial () - Oct 1, 2019 - Abstract #TCT2019TCT_536;
The DCB and DES had comparable 1-year rates of target lesion failure (4.4% vs. 2.6%; p = 0.72). A total of 254 (97.3%) patients have completed 2-year follow-up.Small-Vessel Restore DCB Group (Patients, n = 116; Lesions, n = 116)Small-Vessel Resolute DES Group (Patients, n = 114; Lesions, n = 114)p ValueVery Small-Vessel Group (Patients, n = 32; Lesions, n = 32)Age60.1 ± 10.560.5 ± 10.80.7858.0 ± 9.9Male66.4% (77)77.2% (88)0.0775.0% (24)Diabetes mellitus39.7% (46)42.1% (48)0.7140.6% (13)Reference vessel diameter, mm2.11 ± 0.272.21 ± 0.290.011.86 ± 0.28Lesion length, mm10.5 ± 4.810.8 ± 5.20.6312.2 ± 5.6Post-procedure in-segment diameter stenosis, %19.8 ± 8.812.6 ± 6.4< 0.00123.7 ± 10.19-month in-segment diameter stenosis, % (per lesion)29.3 ± 20.223.9 ± 15.90.0438.4 ± 21.51-year target lesion failure4.4% (5)2.6% (3)0.726.3% (2)1-year def/prob device thrombosis0% (0)0% (0)—0% (0) Conclusion The 2-year clinical follow-up results and other relevant analyses will be presented for the first time at the TCT 2019.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
Efficacy and Safety of the Newer Generation Zotarolimus-Eluting Stent in Routine Clinical Practice: Data From the IRIS-DES Registry () - Oct 1, 2019 - Abstract #TCT2019TCT_238;
After propensity score matching, the adjusted 1-year rate of TVF (adjusted HR: 1.020; 95% CI: 0.767 to 1.356; p = 0.892) was similar between 2 groups. There are no significant interactions in key subgroup analysis.UnivariateMultivariatePropensity MatchingTVF1.134 (0.917–1.401)0.999 (0.775–1.288)1.020 (0.767–1.356)Cardiac death0.952 (0.536–1.691)0.488 (0.209–1.137)0.488 (0.195–1.224)Target vessel myocardial infarction1.022 (0.774–1.350)1.098 (0.818–1.474)1.251 (0.900–1.739)Target vessel revascularization1.052 (0.631–1.752)1.026 (0.573–1.837)0.807 (0.415–1.570)Target lesion revascularization1.229 (0.673–2.246)1.008 (0.513–1.979)0.892 (0.419–1.898) Conclusion Among patients who underwent percutaneous coronary intervention, the use of newer R-ZES showed no significantly different outcomes than for the use of DP-EES.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
Assessing Suitability for Short-Term DAPT: Thromboresistance, Albumin Retention, and Endothelial Function in the Resolute Onyx Zotarolimus Versus BioFreedom Biolimus-Eluting Coronary Stent Systems () - Oct 1, 2019 - Abstract #TCT2019TCT_195;
Regarding endothelial function, RO-DES was similar to BF-DCS. These results suggest superiority for short-term dual antiplatelet therapy for RO-DES versus both Onyx-BMS and BF-DCS.
- |||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical: Onyx ONE slides presented at #TCT2019 suggest the Resolute Onyx stent is safe and effective in high risk patients who received 1 month DAPT. Check out the full deck: https://t.co/TaVI5YsQFl (Twitter) - Sep 29, 2019
- | paclitaxel / Generic Mfg.
Clinical, Clinical data, Journal: Five-year clinical outcomes of first-generation versus second-generation drug-eluting stents following coronary chronic total occlusion intervention. (Pubmed Central) - Sep 27, 2019
Finally, MACE was also similar between the two groups (HR = 1.557, 95% CI: 0.820-2.959, P = 0.176) after PSM. In this study, 2G-DES was not associated with reduced long-term MACE compared with 1G-DES following successful CTO revascularization up to five years.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Surgery: FAME 3: A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease (clinicaltrials.gov) - Sep 19, 2019
P4, N=1500, Recruiting, Sponsor: Stanford University
In this study, 2G-DES was not associated with reduced long-term MACE compared with 1G-DES following successful CTO revascularization up to five years. Trial completion date: Aug 2021 --> Dec 2024 | Trial primary completion date: Aug 2019 --> Dec 2020
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. (Pubmed Central) - Sep 10, 2019
To date the early strut coverage with the second-generation durable-polymer ONYX zotarolimus-eluting stent (O-ZES) is unknown...For all stents, malapposition volume was 47.9 mm at baseline and 51.7 mm at follow-up, giving the late acquired stent malapposition volume of 3.8 mm. The second-generation durable polymer O-ZES showed favorable vessel healing at 30-day OCT follow-up.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal: Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy. (Pubmed Central) - Sep 7, 2019
The second-generation durable polymer O-ZES showed favorable vessel healing at 30-day OCT follow-up. This OCT study indicated that reducing DAPT's duration may provide acceptable arterial healing in patients with implanted R-ZESs.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal, HEOR: Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. (Pubmed Central) - Sep 6, 2019
The SYNTAX score was predictor of major adverse cardiovascular events but not bleeding and ZES provided superior efficacy and safety than BMS across the whole spectrum of CAD complexity. SYNTAX score may be routinely used for the assessment of the ischemic risk (but not bleeding) after PCI and should not guide the decision-making for DES versus BMS in patients undergoing PCI.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal: Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents: A propensity score matching study. (Pubmed Central) - Sep 5, 2019
During the 3-year follow-up period, the cumulative incidence of MACE (hazard ratio [HR], 1.525; 95% confidence interval [CI], 0.920-2.526; P = .101) and ST (HR, 1.248; 95% CI, 0.335-4.4649; P = .741) were similar between P-ZES and B-ZES after PSM. However, TLR rate was significantly higher in ZES-S than ZES-I (11.3% vs 3.8%, log rank P = .029) and TVR rate was higher in ZES-S than ZES-R (14.1% vs 4.8%, log rank P = .025).In this single-center, all-comer registry, despite different polymers, P-ZES, and B-ZES showed comparable safety and efficacy during a 3-year follow-up period after PCI.
- | sirolimus / generics
Clinical, Clinical data, Journal: Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial. (Pubmed Central) - Aug 7, 2019
P=N/A
At two-year follow-up, there was no significant between-DES difference in the rates of the primary endpoint. Landmark analyses provided a signal that the use of SES versus ZES might reduce the risk of repeat revascularisation after one-year follow-up.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Clinical, Journal: Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single Center Experience. (Pubmed Central) - Aug 6, 2019
There were no procedure-related mortalities. Our study confirms the feasibility of deploying DES for the treatment of ostial vertebral artery stenosis with low peri-procedural risk and low medium-term rates of re-stenosis.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Functional comparison between BuMA Supreme biodegradable polymer sirolimus-eluting and durable polymer zotarolimus-eluting coronary stents using Quantitative Flow Ratio: PIONEER QFR substudy. (Pubmed Central) - Aug 3, 2019
Our study confirms the feasibility of deploying DES for the treatment of ostial vertebral artery stenosis with low peri-procedural risk and low medium-term rates of re-stenosis. Quantitative flow assessment nine months after stenting did not differ between B-SES and R-ZES, despite a significant difference in in-stent late lumen loss.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial. (Pubmed Central) - Aug 1, 2019
In-stent late lumen loss is non-inferior, and appears to be superior, with the thin-strut novel composite wire R-Onyx DES compared with Resolute DES. Continued evolution of stent design can improve angiographic outcomes in complex lesions, even in the current era of next-generation DES.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss. (Pubmed Central) - Aug 1, 2019
P4
Despite having a durable polymer, Resolute Integrity zotarolimus-eluting stent exhibited better strut coverage than BioMatrix NeoFlex Biolimus A9-eluting stent having a biodegradable polymer; both showed similar antiproliferative efficacy. This novel, longitudinal, sequential optical coherence tomography protocol using each patient as own control could achieve conclusive results in small sample size.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion, Trial completion date, Trial primary completion date: Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease (clinicaltrials.gov) - Jul 28, 2019
P=N/A, N=240, Completed, Sponsor: ZhuHai Cardionovum Medical Device Co., Ltd.
This novel, longitudinal, sequential optical coherence tomography protocol using each patient as own control could achieve conclusive results in small sample size. Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> May 2019 | Trial primary completion date: Dec 2019 --> Dec 2018
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Journal: In-stent restenosis assessed by frequency-domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents. (Pubmed Central) - Jul 26, 2019
Homogeneous tissue morphology was more frequently found for second-generation than first-generation DES ISR, especially in the late phase. This suggested that neointimal hyperplasia was the main mechanism in second-generation DES ISR, and that the neointima was stabilised, much like in bare metal stent implantation.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal, Real-World Evidence: Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry. (Pubmed Central) - Jul 24, 2019
In this real-world registry, A-SES and ZES seems to be associated with promising 1-year clinical safety outcomes following PCI in a contemporary cohort of high-risk diabetic patients. Our results should be considered hypothesis generating, as the clinical safety of A-SES has to be confirmed in a large trial.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial primary completion date: Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease (clinicaltrials.gov) - Jul 24, 2019
P=N/A, N=260, Active, not recruiting, Sponsor: ZhuHai Cardionovum Medical Device Co., Ltd.
Our results should be considered hypothesis generating, as the clinical safety of A-SES has to be confirmed in a large trial. Trial primary completion date: Dec 2018 --> Dec 2019
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Clinical, Journal: Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. (Pubmed Central) - Jul 19, 2019
P=N/A
In this pooled analysis of 3 prospective registries involving unrestricted use of various second-generation DES for LMCAD, we found no significant between-group differences in 3-year risk of target-vessel failure, except for a higher risk of primary outcome with PtCr-EES compared to BP-BES. (Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice [IRIS-DES]; NCT01186133).
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Clinical, Journal: A prospective randomized trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: 6 months angiographic and 1 year clinical results of the NIREUS trial. (Pubmed Central) - Jul 19, 2019
The BioNIR stent was non-inferior to the Resolute Integrity stent for the primary endpoint of angiographic in-stent LLL at 6 months. Clinical outcomes at one year were comparable between the two groups.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Safety and Efficacy of Zotarolimus-Eluting Stents in the Treatment of Chinese Diabetic Coronary Lesions: The RESOLUTE-DIABETES CHINA Study. (Pubmed Central) - Jul 13, 2019
Resolute ZES may perform well in the Chinese diabetic population, especially in those with poor glucose control, complex lesions, and certain unfavorable clinical features. Further studies are needed to determine why ZES perform well in this population.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Trial completion date, Trial termination, Real-world evidence, Real-world: CHOICE: BES, EES, and ZES-R in Real World Practice (clinicaltrials.gov) - Jul 9, 2019
P=N/A, N=1960, Terminated, Sponsor: Yonsei University
Further studies are needed to determine why ZES perform well in this population. Trial completion date: Jun 2019 --> Jan 2019 | Active, not recruiting --> Terminated; Slow enrollment
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial. (Pubmed Central) - Jun 15, 2019
P=N/A
Trial completion date: Jun 2019 --> Jan 2019 | Active, not recruiting --> Terminated; Slow enrollment At 1-year follow-up, very thin-strut BP-DES showed similar safety and efficacy for treating HBR patients as thin-strut DP-DES.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Effectiveness and Safety of Zotarolimus-Eluting Stent (Resolute™ Integrity) in Patients with Diffuse Long Coronary Artery Disease. (Pubmed Central) - Jun 6, 2019
At 1-year follow-up, very thin-strut BP-DES showed similar safety and efficacy for treating HBR patients as thin-strut DP-DES. Our study shows that R-ZES has an excellent 1-year clinical outcome in Korean patients with DLCAD.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment closed: RESOLUTE ONYX China RCT Study (clinicaltrials.gov) - Jun 4, 2019
P=N/A, N=550, Active, not recruiting, Sponsor: Medtronic Vascular
Our study shows that R-ZES has an excellent 1-year clinical outcome in Korean patients with DLCAD. Recruiting --> Active, not recruiting
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment closed: RESOLUTE ONYX China Single Arm Study (clinicaltrials.gov) - Jun 4, 2019
P=N/A, N=591, Active, not recruiting, Sponsor: Medtronic Vascular
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Xience (everolimus-eluting stent) / Abbott
Clinical, Journal: Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial. (Pubmed Central) - May 30, 2019
P4
Long-term outcome data from nonenrolled eligible patients support the validity of the TWENTE trial findings and present, with the trial, a strong case for the long-term safety and efficacy of the newer-generation DESs used. clinicaltrials.gov Identifier: NCT01066650.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: First-in-man randomized comparison of BuMA Supreme biodegradable polymer sirolimus-eluting versus durable polymer zotarolimus-eluting coronary stents: The PIONEER trial. (Pubmed Central) - May 13, 2019
The PIONEER trial did not meet its primary endpoint in terms of in-stent LLL at 9-month follow-up. However, this result did not translate into any increase in restenosis rate or impairment in 12-month clinical outcomes.
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion, Trial completion date: RI-US XL: Resolute Integrity US Extended Length Sub-Study(RI US XL) (clinicaltrials.gov) - May 8, 2019
P=N/A, N=56, Completed, Sponsor: Medtronic Vascular
However, this result did not translate into any increase in restenosis rate or impairment in 12-month clinical outcomes. Active, not recruiting --> Completed | Trial completion date: Oct 2020 --> Dec 2018
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Retrospective data, Journal: Impact of early (3 months) dual antiplatelet treatment interruption prior to renal transplantation in patients with second-generation DES on perioperative stent thrombosis and MACEs. (Pubmed Central) - May 7, 2019
Active, not recruiting --> Completed | Trial completion date: Oct 2020 --> Dec 2018 Early (3 months) interruption of antiplatelet treatment with second-generation stents before renal transplantation seems to be safe and does not lead to increase in the occurrence of ST and MACEs.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Clinical, Journal: 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial. (Pubmed Central) - May 7, 2019
Early (3 months) interruption of antiplatelet treatment with second-generation stents before renal transplantation seems to be safe and does not lead to increase in the occurrence of ST and MACEs. At 5-year follow-up, the Resolute Integrity ZES and PROMUS Element EES showed similar and sustained results in terms of safety and efficacy for treating a broad population of all-comers.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Safety of 6-Month Dual-Antiplatelet Therapy after Second-Generation Drug-Eluting Stent Implantation: OPTIMA-C Randomized Clinical Trial and OCT Substudy. (Pubmed Central) - Apr 26, 2019
P4
OCT examination revealed favorable stent strut coverage at 6 months after stent implantation. The current trial is registered under ClinicalTrials.gov, Identifier (NCT03056118).
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, NN1213 / Novo Nordisk, Xience (everolimus-eluting stent) / Abbott
Trial completion, Phase classification, Enrollment change: Intravascular ULTrasound Guided Versus Conventional Angiography Guided Strategy to Deploy Zotarolimus and Everolimus Eluting Third Generation Stents in the Long Coronary Artery Lesions: ULTRA-ZET Trial (clinicaltrials.gov) - Apr 20, 2019
P=N/A, N=568, Completed, Sponsor: Yonsei University
The current trial is registered under ClinicalTrials.gov, Identifier (NCT03056118). Recruiting --> Completed | Phase classification: P4 --> PN/A | N=1116 --> 568
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: New-onset atrial fibrillation after percutaneous coronary intervention or coronary artery bypass grafting for left main disease. (Pubmed Central) - Apr 19, 2019
...The patients with LMCAD and low or intermediate SYNTAX score were randomized to PCI with zotarolimus-eluting stents versus CABG...Conclusion The NOAF was common after CABG, but extremely rare after PCI, and it occurred almost exclusively following CABG. There was a clear statistical tendency for all-cause death, cardiovascular death and stroke at 6-month follow-up period.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment closed: A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear) (clinicaltrials.gov) - Apr 17, 2019
P=N/A, N=800, Active, not recruiting, Sponsor: Medtronic Vascular
There was a clear statistical tendency for all-cause death, cardiovascular death and stroke at 6-month follow-up period. Recruiting --> Active, not recruiting
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion: Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study (clinicaltrials.gov) - Apr 3, 2019
P=N/A, N=75, Completed, Sponsor: Medtronic Vascular
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion: Medtronic Resolute Onyx 2.0 mm Clinical Study (clinicaltrials.gov) - Apr 3, 2019
P=N/A, N=101, Completed, Sponsor: Medtronic Vascular
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial primary completion date: Onyx ONE: A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients (clinicaltrials.gov) - Mar 15, 2019
P=N/A, N=2000, Active, not recruiting, Sponsor: Medtronic Vascular
Active, not recruiting --> Completed Trial primary completion date: Jan 2019 --> Sep 2018
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial primary completion date: ONYX PAS: RESOLUTE ONYX Post-Approval Study (clinicaltrials.gov) - Mar 6, 2019
P=N/A, N=510, Recruiting, Sponsor: Medtronic Vascular
Trial primary completion date: Jan 2019 --> Sep 2018 Trial primary completion date: Feb 2019 --> Nov 2019
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Trial completion date, Trial primary completion date: SHEAR-STENT: Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels (clinicaltrials.gov) - Jan 23, 2019
P=N/A, N=126, Recruiting, Sponsor: Emory University
Trial primary completion date: Feb 2019 --> Nov 2019 Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Jun 2020
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date, Trial primary completion date: The IRIS-Resolute Integrity (IRIS-Integrity) (clinicaltrials.gov) - Dec 21, 2018
P=N/A, N=3000, Active, not recruiting, Sponsor: Seung-Jung Park
Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Jun 2020 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Jul 2018 --> Jan 2016
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date, Trial primary completion date: IRIS-Onyx Cohort in the IRIS-DES Registry (clinicaltrials.gov) - Dec 21, 2018
P=N/A, N=4000, Recruiting, Sponsor: Seung-Jung Park
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Jul 2018 --> Jan 2016 Trial completion date: Oct 2022 --> Sep 2025 | Trial primary completion date: Oct 2018 --> Sep 2021
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment closed: Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI (clinicaltrials.gov) - Nov 7, 2018
P=N/A, N=932, Active, not recruiting, Sponsor: Keimyung University Dongsan Medical Center
Trial completion date: Oct 2022 --> Sep 2025 | Trial primary completion date: Oct 2018 --> Sep 2021 Recruiting --> Active, not recruiting
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment closed: Onyx ONE: A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=2000, Active, not recruiting, Sponsor: Medtronic Vascular
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Enrollment open: A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear) (clinicaltrials.gov) - Oct 9, 2018
P=N/A, N=800, Recruiting, Sponsor: Medtronic Vascular
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
New trial: A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear) (clinicaltrials.gov) - Aug 26, 2018
P=N/A, N=800, Not yet recruiting, Sponsor: Medtronic Vascular
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Phase classification, Enrollment change, Trial withdrawal: Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents (clinicaltrials.gov) - Aug 3, 2018
P=N/A, N=0, Withdrawn, Sponsor: Hyogo College of Medicine
Not yet recruiting --> Recruiting Phase classification: P4 --> P=N/A | N=60 --> 0 | Recruiting --> Withdrawn